Compare Dishman Pharma with Wockhardt - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DISHMAN PHARMA vs WOCKHARDT - Comparison Results

Rs 100 invested in...

Loading...
DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DISHMAN PHARMA WOCKHARDT DISHMAN PHARMA/
WOCKHARDT
 
P/E (TTM) x 30.0 -54.4 - View Chart
P/BV x 3.3 1.2 276.5% View Chart
Dividend Yield % 0.7 0.0 -  

Financials

 DISHMAN PHARMA   WOCKHARDT
EQUITY SHARE DATA
    DISHMAN PHARMA
Mar-16
WOCKHARDT
Mar-21
DISHMAN PHARMA/
WOCKHARDT
5-Yr Chart
Click to enlarge
High Rs374570 65.7%   
Low Rs129174 74.2%   
Sales per share (Unadj.) Rs197.0249.3 79.0%  
Earnings per share (Unadj.) Rs21.262.2 34.1%  
Cash flow per share (Unadj.) Rs34.784.4 41.1%  
Dividends per share (Unadj.) Rs2.000-  
Avg Dividend yield %0.80-  
Book value per share (Unadj.) Rs179.9302.3 59.5%  
Shares outstanding (eoy) m80.70110.78 72.8%   
Bonus / Rights / Conversions 00-  
Price / Sales ratio x1.31.5 85.7%   
Avg P/E ratio x11.96.0 198.5%  
P/CF ratio (eoy) x7.34.4 164.5%  
Price / Book Value ratio x1.41.2 113.8%  
Dividend payout %9.40-   
Avg Mkt Cap Rs m20,30741,188 49.3%   
No. of employees `000NANA-   
Total wages/salary Rs m5,3557,630 70.2%   
Avg. sales/employee Rs Th00-  
Avg. wages/employee Rs Th00-  
Avg. net profit/employee Rs Th00-  
INCOME DATA
Net Sales Rs m15,89827,620 57.6%  
Other income Rs m2651,534 17.3%   
Total revenues Rs m16,16329,155 55.4%   
Gross profit Rs m4,10312,575 32.6%  
Depreciation Rs m1,0912,460 44.3%   
Interest Rs m9442,491 37.9%   
Profit before tax Rs m2,3349,159 25.5%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m6242,273 27.4%   
Profit after tax Rs m1,7106,886 24.8%  
Gross profit margin %25.845.5 56.7%  
Effective tax rate %26.724.8 107.7%   
Net profit margin %10.824.9 43.1%  
BALANCE SHEET DATA
Current assets Rs m11,01824,244 45.4%   
Current liabilities Rs m9,51731,182 30.5%   
Net working cap to sales %9.4-25.1 -37.6%  
Current ratio x1.20.8 148.9%  
Inventory Days Days5730 188.6%  
Debtors Days Days312 28.8%  
Net fixed assets Rs m18,78749,508 37.9%   
Share capital Rs m161554 29.1%   
"Free" reserves Rs m14,35432,939 43.6%   
Net worth Rs m14,51633,492 43.3%   
Long term debt Rs m4,1895,029 83.3%   
Total assets Rs m29,80573,752 40.4%  
Interest coverage x3.54.7 74.2%   
Debt to equity ratio x0.30.2 192.2%  
Sales to assets ratio x0.50.4 142.4%   
Return on assets %8.912.7 70.0%  
Return on equity %11.820.6 57.3%  
Return on capital %17.530.2 57.9%  
Exports to sales %24.90-   
Imports to sales %3.71.8 207.2%   
Exports (fob) Rs m3,956NA-   
Imports (cif) Rs m594498 119.2%   
Fx inflow Rs m4,9521,009 490.7%   
Fx outflow Rs m697498 139.8%   
Net fx Rs m4,255511 833.1%   
CASH FLOW
From Operations Rs m2,786-2,873 -97.0%  
From Investments Rs m-1,52914,701 -10.4%  
From Financial Activity Rs m-941-11,708 8.0%  
Net Cashflow Rs m317129 245.2%  

Share Holding

Indian Promoters % 61.4 67.1 91.5%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 23.0 3.0 770.1%  
FIIs % 12.0 2.9 415.6%  
ADR/GDR % 0.0 0.0 -  
Free float % 38.6 32.9 117.4%  
Shareholders   52,291 172,460 30.3%  
Pledged promoter(s) holding % 0.0 43.6 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DISHMAN PHARMA With:   CIPLA    SUN PHARMA    LUPIN    DR. REDDYS LAB    ZYDUS LIFESCIENCES    



Today's Market

Sensex, Nifty End Marginally Lower; Metal Stocks Witness Selling(Closing)

After opening on a positive note, Indian share markets failed to keep up early gains and ended the day marginally lower.

Related Views on News

3 Indian Pharma Companies that are Investing Big Time for the Future (Views On News)

Nov 9, 2021

In 2021, R&D of pharma companies roared to life in a never-before-seen way.

5 Indian Pharma Companies Riding the Vaccination Wave (Views On News)

Sep 3, 2021

These companies are likely to benefit the most from Covid-19 vaccines.

Divi's Lab Net Profit Rises 78%. Company Declares 1,500% Dividend (Views On News)

May 23, 2022

For full year, profit figures stood at Rs 29.6 bn as against Rs 19.8 bn for the previous year, reflecting a growth of 49%.

Dr Reddy's Net Profit Falls 76%. Company Declares 600% Dividend (Views On News)

May 19, 2022

During Q4, there were many changes to the products forming part of Dr Reddy's generics and proprietary products segments.

Cipla vs Sun Pharma: Which Pharma Stock is Better? (Views On News)

Apr 13, 2022

The pandemic has opened up new opportunities for the Indian pharmaceutical sector. Which company is set to benefit from it?

More Views on News

Most Popular

2022's Best Performing Penny Stocks So Far...(Views On News)

Mar 2, 2022

We are just two months into 2022 and several penny stocks that we track have already surged 5x.

5 Debt Free Penny Stocks with Good Profitability to Watch Out for in 2022(Views On News)

Mar 16, 2022

Debt free penny stocks are vital when it's a question of portfolio diversification in a volatile market. They can potentially offer good profitability in the long run.

Penny Stocks to Buy and Hold Beyond 2022(Views On News)

Apr 6, 2022

A step-by-step method to pick the best penny stocks for the long term.

6 Penny Stocks that Could Be Hidden Bluechips. Take a Look...(Views On News)

Apr 13, 2022

These penny stocks can become future multibaggers. Watch out for them.

Adani Power vs Tata Power: Which Power Stock is Better?(Views On News)

Feb 28, 2022

Rising electricity consumption provides a lot of scope for growth. Which company has a better chance at capturing it?

More

Become A Smarter Investor
In Just 5 Minutes

Multibagger Stock Guide 2022
Get our special report Multibagger Stocks Guide (2022 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

DISHMAN PHARMA SHARE PRICE


May 29, 2017 (Close)

TRACK DISHMAN PHARMA

  • Track your investment in DISHMAN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DISHMAN PHARMA

DISHMAN PHARMA 8-QTR ANALYSIS

COMPARE DISHMAN PHARMA WITH

MARKET STATS